Rhinomed Ltd
Rhinomed Ltd is an Australian medical technology company that develops wearable nasal devices — Rhinoswab and Rhinoswab Junior diagnostic swabs, plus Mute and Turbine consumer nasal dilators — serving healthcare providers, government health departments, retail pharmacy networks, and licensing partners across more than 20 countries.
- Company typePublic
- Founded2006
- HeadquartersVictoria Valley, Australia
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Rhinomed Ltd does
Rhinomed Ltd is an Australian medical technology company that develops wearable nasal technology products addressing respiratory, sleep, athletic, and diagnostic applications. Its proprietary platform leverages nasal airway physiology and is protected by a family of over 60 patents and 57 design patents globally. The company markets four core products: Rhinoswab and Rhinoswab Junior — patented self-administered nasal sampling devices for upper respiratory pathogen detection including SARS-CoV-2, influenza, and RSV, with clinical evidence of equivalent accuracy to combined nose-and-throat swabs and 98% patient comfort rates; and Mute and Turbine — consumer nasal dilators marketed respectively for snoring reduction and sports performance, each demonstrated to increase nasal airflow by up to 38%.
The company operates a dual business model. Consumer revenue is generated through direct-to-consumer e-commerce (rhinomedshop.com and regional storefronts) plus retail pharmacy distribution across more than 20,000 pharmacies worldwide including CVS in the US. B2B medical device revenue is generated through direct sales to hospitals, pathology laboratories, and government health departments, supplemented by exclusive distribution agreements — notably SureScreen Australia for lateral flow point-of-care kits across AU/NZ/Singapore/South Pacific, plus BioTrading Benelux and AntiMicrobial Technologies Group. A third revenue stream consists of licensing royalties from a 12-year exclusive agreement with Columbia Care LLC for nasal cannabinoid delivery in the US market.
The company is headquartered in Cremorne, Victoria, with a regional US office at 41 Madison Avenue, New York, and operates through a wholly-owned subsidiary, ASAP BreatheAssist Pty Ltd. FY24 unaudited revenue reached A$9.2 million, up 21% year on year. Rhinomed was removed from the official ASX list in February 2024, and in April 2025 entered into a Bid Implementation Agreement with Rhinomed Health Corporation, which has subsequently taken its stake above 50% — signaling an active change of control. Management is led by CEO Michael Johnson and Chairman Ron Dewhurst, with Associate Professor John McBain AO as Non-Executive Director.
Rhinomed Ltd firmographics
Firmographics- Name
- Rhinomed Ltd
- Legal name
- Rhinomed Limited
- Website
- https://rhinomed.global
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Rhinomed Ltd is an Australian medical technology company that develops wearable nasal devices — Rhinoswab and Rhinoswab Junior diagnostic swabs, plus Mute and Turbine consumer nasal dilators — serving healthcare providers, government health departments, retail pharmacy networks, and licensing partners across more than 20 countries.
- Ownership category
- akta.pro rank
Rhinomed Ltd industry classification
Industry- Product category
- Respiratory Medical Devices
- NAICS
- Toilet Preparation Manufacturing (325620)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)
- akta.pro secondary industries
- Eye, Ear & Nasal Care (HLAIADAF), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
Keywords
Where Rhinomed Ltd is headquartered
LocationHeadquarters
- HQ city
- Victoria Valley
- HQ country
- Australia
- HQ region
- Oceania
Offices3 records
Markets served
Rhinomed Ltd business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Consumer Nasal Devices Sales: Sale of Mute (anti-snoring sleep device), Turbine (sports breathing aid), and other nasal breathing products directly to consumers via e-commerce platforms and through retail pharmacy distribution.
- Medical Device Sales (Rhinoswab): Sale of Rhinoswab and Rhinoswab Junior nasal swabs to healthcare providers, pathology laboratories, government health departments, and point-of-care testing companies. Minimum order quantity of 1000 swabs for commercial use.
- Technology Licensing: 12-year exclusive licensing agreement with Columbia Care LLC for use of Rhinomed's nasal platform technology for delivery of cannabinoid formulations in the US market.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Rhinoswab commercial pricing for healthcare providers and pathology labs |
| Other | One time/ perpetual license | Trial samples for evaluation purposes |
Go-to-market motion3 records
Distribution channels7 records
Marketing channels6 records
Rhinomed Ltd product offering
Product offeringCore offering
Rhinomed designs, manufactures, and commercialises wearable nasal medical devices spanning respiratory diagnostics (Rhinoswab and Rhinoswab Junior nasal sampling swabs for COVID-19 and other upper respiratory pathogens), sleep and snoring management (Mute nasal dilator), and sports breathing performance (Turbine nasal dilator). Products are sold through consumer retail pharmacies and e-commerce, as well as directly to pathology labs, hospitals, and government health departments, with additional technology licensing for cannabinoid nasal drug delivery.
Product overview
Rhinomed is a wearable nasal technology company offering four main product lines. Rhinoswab and Rhinoswab Junior are nasal sampling devices for respiratory disease diagnosis - Rhinoswab is designed for adults while Rhinoswab Junior is the world's first child-friendly nasal swab for children 4+ years. Mute is a nasal dilator addressing snoring and sleep quality by increasing nasal airflow by 38%. Turbine is a sports-focused nasal dilator that enhances breathing during athletic performance by up to 38%. All products leverage Rhinomed's patented nasal technology platform protected by over 60 patents globally.
Differentiator
Problem solved
Functional benefit
Brands
- Mute: Nasal breathing aid for snoring and sleep improvement.
- Turbine
- Rhinoswab
- Rhinoswab Junior
- Pronto
Products and services
- Rhinoswab Patented comfortable, self-administered nasal swab providing high-yield sampling for COVID-19 and upper respiratory pathogens including influenza and RSV. Clinically validated as equivalent to combined nose-and-throat swab for SARS-CoV-2 detection and compatible with RT-PCR and rapid antigen testing. Sold to healthcare providers, pathology labs and government health departments with a minimum order quantity of 1,000 swabs.
- Rhinoswab Junior The world's first nasal swab designed specifically for children aged 4 years and over, with a child-friendly design that reduces anxiety around testing while providing standardised, comfortable sample collection. Validated for PCR and rapid antigen tests with 91% sensitivity and 99% specificity in detecting paediatric respiratory viruses.
- Mute Nasal dilator device designed to reduce snoring and improve sleep quality by dilating nasal passages, delivering on average 38% more airflow through the nose to reduce mouth breathing. Sold directly to consumers via e-commerce and retail pharmacies worldwide.
- Turbine Nasal dilator designed for athletes that assists with nasal obstruction and congestion during aerobic activity, delivering up to 38% more airflow to help athletes take one extra breath during track, field, bike, or workout activity. Sold directly to consumers via e-commerce and sports retail channels.
Quantifiable outcome
- Up to 38% increase in nasal airflow with Mute and Turbine devices
- +5 more outcomes
Companies that use Rhinomed Ltd
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles5 records
Rhinomed Ltd technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Rhinomed Ltd partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, minor and support.
- SureScreen AustraliacoreExclusive supply agreement for Rhinoswab and Rhinoswab Junior products for inclusion in SureScreen's lateral flow point of care test kits. Covers Australian, New Zealand, Singapore, and South Pacific markets. First product was SARS-CoV-2 Antigen Rapid Test Cassette for children featuring Rhinoswab Junior.
- AntiMicrobial Technologies Group (AMTG)minorDistributor of Rhinoswab products in Western Australia.
- BioTrading Benelux BVminorDistributor of Rhinoswab products in Belgium, Netherlands, and Luxembourg (Benelux region).
- Columbia Care LLCcore12-year exclusive licensing agreement for Rhinomed's nasal platform technology for delivery of cannabinoid formulations in the US market. Columbia Care is the largest medical cannabis operator in the United States. Enables nasally delivered, dose-controlled cannabinoid medicines.
- Medical Device Safety Service GmbH (MDSS)supportAuthorized Representative per EU Regulation 2017/745 (MDR) enabling Rhinomed's CE Mark certification and market access in Europe.
Scale indicators7 records
Recent moves9 records
Expansion highlights6 records
Rhinomed Ltd competitors and assessment
Company assessmentBroad incumbents
- ResMed: Global leader in sleep-disordered breathing and respiratory care devices (CPAP, masks, diagnostics). Overlaps with Rhinomed's Mute sleep technology in the broader sleep-and-snoring patient pathway, though it operates at significantly larger scale across different device categories.
- Fisher & Paykel Healthcare: New Zealand-based respiratory care and humidification device manufacturer. Adjacent peer given Rhinomed's nasal airflow and respiratory health focus (Mute, Turbine), though it serves primarily hospital and home respiratory care rather than OTC nasal dilators.
- Koninklijke Philips (Sleep & Respiratory): Global healthcare major with a sleep and respiratory portfolio (CPAP, oxygen therapy, nebulization). Comparable to Rhinomed at the broad respiratory care category level, with overlap in addressing nasal airflow and sleep-disordered breathing consumers.
- Becton, Dickinson and Company (BD): Global medical technology giant with a substantial diagnostic specimen collection and microbiology portfolio. Competes with Rhinomed's Rhinoswab across healthcare systems and pathology labs and also operates in adjacent sample preparation and respiratory testing workflows.
- Hologic: Major women's health and diagnostic company with significant molecular respiratory testing franchise (e.g., Panther system, SARS-CoV-2 assays). Indirectly comparable to Rhinomed as a downstream consumer of high-quality nasal sample collection devices.
Direct peers
- Church & Dwight (Breathe Right): Owner of the Breathe Right brand, the dominant OTC external nasal dilator strip. Directly competes with Rhinomed's Mute product in the snoring and nasal congestion consumer retail channel, including 20,000+ global pharmacy distribution.
- Copan Diagnostics: Italian-headquartered global leader in pre-analytic specimen collection, including the Copan ESwab, which is the explicit clinical benchmark against which Rhinomed's Rhinoswab is compared. Directly competes with Rhinomed in the nasal swab sample collection market.
- Puritan Medical Products: US-based manufacturer of flocked swabs and specimen collection devices, including products for COVID-19, influenza, and RSV testing. Directly competes with Rhinoswab in the diagnostic nasal swab category.
Emerging players
- Aptar Pharma: Specialist in nasal and pulmonary drug delivery systems and device components for pharmaceutical partners. Comparable to Rhinomed's nasal drug delivery platform and Columbia Care-style licensing model, with a focus on enabling third-party nasal therapeutics.
- NoseWings / Max-Air Nose Cones: Smaller OTC nasal dilator brands targeting athletes and snorers. Comparable as niche emerging players in the same consumer nasal dilator category where Rhinomed's Mute and Turbine compete.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Rhinomed Ltd social profiles
Digital presenceRhinomed Ltd compliance and trust
Trust signalCompliance9 records
Rhinomed Ltd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rhinomed Ltd leadership team
Management profileNumber of profiles
Profiles4 records
Rhinomed Ltd subsidiaries and ownership
Company hierarchySubsidiaries1 record
Rhinomed Ltd funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rhinomed Ltd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rhinomed Ltd
What does Rhinomed Ltd do?
Rhinomed designs, manufactures, and commercialises wearable nasal medical devices spanning respiratory diagnostics (Rhinoswab and Rhinoswab Junior nasal sampling swabs for COVID-19 and other upper respiratory pathogens), sleep and snoring management (Mute nasal dilator), and sports breathing performance (Turbine nasal dilator). Products are sold through consumer retail pharmacies and e-commerce, as well as directly to pathology labs, hospitals, and government health departments, with additional technology licensing for cannabinoid nasal drug delivery.
Is Rhinomed Ltd a public or private company?
Rhinomed Ltd is a public company. It is classified as corporate owned and is currently operating.
When was Rhinomed Ltd founded?
Rhinomed Ltd was founded in 2006. It employs 11 to 50 people.
Where is Rhinomed Ltd based?
Rhinomed Ltd is headquartered in Victoria Valley, Australia, in the Oceania region.
How does Rhinomed Ltd make money?
Three revenue lines are on record. Consumer Nasal Devices Sales are the primary driver. The others are medical Device Sales (Rhinoswab) and technology Licensing.
Who are Rhinomed Ltd's main competitors?
Broad incumbents on record are ResMed, Fisher & Paykel Healthcare, Koninklijke Philips (Sleep & Respiratory), Becton, Dickinson and Company (BD) and Hologic. Direct peers are Church & Dwight (Breathe Right), Copan Diagnostics and Puritan Medical Products. Emerging players are Aptar Pharma and NoseWings / Max-Air Nose Cones.
Does Rhinomed Ltd have an API?
No public API is recorded for Rhinomed Ltd.
What industry is Rhinomed Ltd in?
Rhinomed Ltd's product category is Respiratory Medical Devices. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices), with a secondary code of HLAIADAF, Eye, Ear & Nasal Care. Its NAICS code is 325620 and its SIC code is 3841.